Abstract
Background: Simvastatin and atorvastatin are effective statins for treating hypercholesterolemia.
Hypothesis: The study was undertaken to compare the efficacy and tolerability of simvastatin 20 and 40 mg/day and atorvastatin 10 and 20 mg/day.
Methods: In this multinational, open‐label, crossover study, 258 patients with primary hypercholesterolemia were randomized after 4 weeks of diet plus placebo to once‐daily administration of a starting dose sequence of simvastatin (20 mg) or atorvastatin (10 mg), or a higher dose sequence of simvastatin (40 mg) or atorvastatin (20 mg) for 6 weeks. Patients were then switched after a 1‐week washout to the corresponding starting or higher dose of the alternate drug for a second 6‐week period. The primary endpoint was the mean percent change from baseline to Week 6 in low‐density lipoprotein (LDL) cholesterol; percent changes from baseline in total cholesterol, high‐density lipoprotein cholesterol, triglycerides, and apolipoprotein B were also compared. Safety was assessed through adverse experiences and laboratory measurements.
Results: Both statins produced statistically significant improvements in all measured plasma lipids and lipoproteins. The main treatment comparison showed no statistically significant difference in changes in LDL cholesterol and triglycerides, whereby the overall effects were comparable when doses of 20 mg and 40 mg of simvastatin were compared with atorvastatin 10 mg and 20 mg. The mean percent reductions for LDL cholesterol from baseline to Week 6 ranged from 35–42% for the entire study cohort. An LDL cholesterol level ≤ 130 mg/dl (3.4 mmol/l) was achieved in approximately 70% of patients treated with both drugs in this study. Simvastatin and atorvastatin were well tolerated at the doses studied.
Conclusion: In patients with hypercholesterolemia, the most commonly used doses of simvastatin and atorvastatin produced similar changes in LDL cholesterol and achieved an LDL cholesterol level ≤ 130 mg/dl (3.4 mmol/l) in a similar number of patients. Both statins were well tolerated.
Keywords: simvastatin, atorvastatin, 3‐hydroxy‐3‐methyl‐glutaryl coenzyme A reductase inhibitors, hypercholesterolemia, low‐density lipoprotein cholesterol, triglycerides
Full Text
The Full Text of this article is available as a PDF (833.0 KB).
References
- 1. Levine GH, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms (review). N Engl J Med 1995; 332: 512–521 [DOI] [PubMed] [Google Scholar]
- 2. Anderson KM, Catelli WP, Levy D: Cholesterol and mortality 30 years of follow‐up from the Framingham study. J Am Med Assoc 1987; 257: 2176–2180 [DOI] [PubMed] [Google Scholar]
- 3. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W: Serum cholesterol and coronary heart disease in populations with low cholesterol concentration. Br Med J 1991; 303: 276–282 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. National Cholesterol Education Program Expert Panel : Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015–3023 [PubMed] [Google Scholar]
- 5. Mingworth DR, Bacon SP, Larsen KK: Long‐term experience with HMG CoA reductase inhibitors in the therapy of hypercholesterolemia. Atheroscler Rev 1988; 18: 161–187 [Google Scholar]
- 6. ZOCOR™ (simvastatin) tablets . Product information (1998) Merck & Co., Inc., Whitehouse Station, N.J., USA: [Google Scholar]
- 7. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
- 8. Pedersen TR, Wilhelmsen L, Faergeman O, Thorgeirsson TG, Troedsson L, Kristianson J, Cook TJ, Kjekshus J: Extended follow‐up of patients in the Scandinavian Simvastatin Survival Study (4S) shows increased survival benefit of simvastatin therapy (abstr). Circulation 1998; 98 (17 suppl) () I–451 [Google Scholar]
- 9. MAAS Investigators : Effect of simvastatin on coronary artheroma: The Multicentre Anti‐Atheroma Study (MAAS). Lancet 1994; 344: 633–638 [PubMed] [Google Scholar]
- 10. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM: Reduction of LDL‐cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG‐CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995; 15: 678–682 [DOI] [PubMed] [Google Scholar]
- 11. Bertolini S, Bon GB, Campbell LM, Farmer M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW: Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191–197 [DOI] [PubMed] [Google Scholar]
- 12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low‐density lipoprotein cholesterol in plasma, without use of preparative ultracentrif uge. Clin Chem 1977; 18: 499–502 [PubMed] [Google Scholar]
- 13. Best J, Dart A, Hamilton Craig I, Jerums G, Nicholson G, Sullivan D, Tallis G, West M, d'Emden M, Braes P: A One Year Study Comparing Atorvastatin and Simvastatin in Patients with Hypercholesterolemia. 66th Congress of the European Atherosclerosis Society, July 1996. [DOI] [PubMed]
- 14. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 23: 3015–3023 [PubMed] [Google Scholar]
- 15. Hulley SB, Rosenman RH, Bowol RD, Brand RJ: Epidemiology as a guide to clinical decisions: The association between triglyceride and coronary heart disease. N Engl J Med 1980; 302: 1383–1389 [DOI] [PubMed] [Google Scholar]
- 16. Castelli WP: The triglyceride issue: A view from Framingham. Am Heart J 1984; 112: 432–437 [DOI] [PubMed] [Google Scholar]
- 17. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb Vase Biol 1991; 11: 2–14 [DOI] [PubMed] [Google Scholar]
- 18. Stein EV, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81 (4A): 66B–69B [DOI] [PubMed] [Google Scholar]
- 19. Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, Mount J, Painter R, Parish S, Slavin B, Sleight P, Youngman L, Peto R, for the Oxford Cholesterol Group: Three‐year follow‐up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255–269 [DOI] [PubMed] [Google Scholar]
- 20. Neuman MP, Neuman HR, Neuman J: Significant increase of high‐density lipoprotein2‐cholesterol under prolonged simvastatin treatment. Atherosclerosis 1991; 91: S11–S19 [DOI] [PubMed] [Google Scholar]
- 21. The Simvastatin Pravastatin Study Group : Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408–1414 [DOI] [PubMed] [Google Scholar]